H5N1 influenza vaccine: Phase I started

Not-for-profit Fraunhofer USA Center for Molecular Biotechnology (Newark, Del.) began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate HAI-05 in 260 volunteers. Fraunhofer...